Peltz About PepsiCo, Inc. (PEP) and Buffett’s Stake in The Coca-Cola Company (KO)

CNBC viewers and participants at the Delivery Alpha conference yesterday had a ring side view on the storied rivalry between the camp followers of American beverage majors PepsiCo, Inc. (NYSE:PEP) and The Coca-Cola Company (NYSE:KO) when Nelson Peltz who is the founder and the chief executive officer of Trian Fund Management took objection to the fact that interviewers at CNBC were seeking investor tips on PepsiCo, Inc. (NYSE:PEP) stock from investment guru Warren Buffett.


The audience chuckled when Nelson Peltz who owns a significant chunk of stock in PepsiCo, Inc. (NYSE:PEP) questioned gruffly the propriety of interviewers at CNBC seeking the Warren Buffet’s views on holding shares of PepsiCo, Inc. (NYSE:PEP), overlooking the fact that Mr. Buffett is one of the largest individual and long time investors in The Coca-Cola Company (NYSE:KO).

Mr. Peltz took CNBC interviewer Andrew to task for “twice seeking Mr Buffett advice to share holders of PepsiCo, Inc. (NYSE:PEP)” and “then never telling the audience that he (Buffett) is the largest share holder in Coke, and you never told the audience that he’s been on the board forever and his son’s on the board right now”.

Mr. Peltz then compared the lack of disclosure about Mr Buffett interest in rival The Coca-Cola Company (NYSE:KO) during CNBC interviews with various analysts who commented on company stock, disclosing to their viewers and readers any existing interests in the stock that they or their family members hold.

Mr. Peltz concluded by sarcastically commenting that: “I want you all to know that, next time you get Pepsi advice from the largest shareholder of Coke.”

Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!